ALEPH-2
ALEPH-2 is a rare psychedelic of the substituted amphetamine and phenethylamine classes, belonging to both the Aleph series and DOx family. First described by Alexander Shulgin in 1978 and later documented in his 1991 book PiHKAL, it functions as the DOx analogue of 2C-T-2.12 It is reported to be potent and to produce long-lasting, highly visual experiences.32 Very little human use data is available.
Contents
Dosage & Duration
Dosage
Suspected to be potent, with substantial individual variation in response; one report described strong effects at 4 mg while another described only a bare threshold at 8 mg.
Duration
Subjective Effects
ALEPH-2 produces a long-lasting psychedelic state that is notably unpredictable in both potency and character. Responses vary dramatically between individuals and occasions: one report describes 4 mg producing incapacitation with a fetal position, hours of relative hibernation, and substantial amnesia, while another describes 8 mg yielding only a bare threshold with slight lightheadedness. Visual effects show the same inconsistency, ranging from almost entirely absent to extraordinary distortions and near-hallucinatory illusions. Effects can continue climbing for two hours or more, with residual shakiness, tremor, and disturbed sleep persisting well into the night.
Physical
The body load includes mental and physical stimulation, restlessness, muscle tension, and a sensation of physical warmth alongside sweating and chills. The offset is marked by residual shakes, muscular tremor, muscular weakness, jaw tension, and insomnia.
Cognitive
The headspace can include euphoria, enhanced empathy, insight, and a softening of the ego, but also confusion and a markedly solipsistic quality at strong doses, in which the user feels like the center of their world and distrusts that others share the same reality. Interpretive shifts can render mundane environments magical or strip expected wonder from novel ones.
Emotional
Visual
Visual effects are highly variable between experiences, from almost none at 8 mg to extraordinary distortion and illusion at 5 mg.
Auditory
Tactile
Reagent Testing
Loading reagent data
Pharmacology
Pharmacodynamics
ALEPH-2 acts as a serotonin 5-HT2 receptor agonist.4 It also functions as a weak monoamine oxidase inhibitor, with substantially greater potency at MAO-A (IC50 3,200 nM) compared to MAO-B (IC50 >100,000 nM).5
Pharmacokinetics
Tolerance
Serotonergic psychedelics (LSD, psilocybin, mescaline, DOx compounds), Other 5-HT2A agonists
Harm Potential
Toxicity
Muscle tension, considerable muscular tremor, and marked muscular weakness have been reported during intoxication, sometimes persisting for hours after the peak effects subside.
Psychosis Risk
Confusion has been reported as an acute effect. One case at 4 mg produced substantial amnesia and a state of relative hibernation lasting several hours, though explicit psychotic symptoms have not been documented.2
History & Culture
ALEPH-2 was first introduced to the scientific literature by Alexander Shulgin in 1978 as part of his systematic exploration of phenethylamine derivatives.1 The compound belongs to the Aleph series, a family of sulfur-substituted psychedelic amphetamines that Shulgin…
Legality
By Country
References
Source Pages
Bluelight: ALEPH-2 4.2mg trip report- Bluelight: ALEPH-2 discussion thread
- Bluelight: community caution on sulfur-substituted phenethylamines (DOT/ALEPH thread)
- Bluelight: The Big and Dandy DOT/ALEPH-1 Thread
DrugBank: 2,5-Dimethoxy-4-ethylthioamphetamine
Erowid ALEPH-2 Experience: The Continuum Hypothesis
Isomer Design (TiHKAL/PiHKAL)- PiHKAL #4 ALEPH-2 (isomerdesign mirror)
- PiHKAL.info - ALEPH-2 Chemical Data
Wikipedia
Citations
- Braun, Ulrich, Braun, Gisela, Jacob III, Peyton, Nichols, David E., & Shulgin, Alexander T.. (1978). Mescaline Analogs: Substitutions at the 4-Position. QuaSAR: Quantitative Structure Activity Relationships of Analgesics, Narcotic Antagonists, and Hallucinogens, 27-37. https://chemistry.mdma.ch/hiveboard/rhodium/pdf/nida.monograph.22.qsar.pdf12
- Alexander Shulgin, & Ann Shulgin. (1991). PiHKAL #4: ALEPH-2. PiHKAL: A Chemical Love Story. https://erowid.org/library/books_online/pihkal/pihkal004.shtml123456
- Shulgin, Alexander, Manning, Tania, & Daley, Paul F.. (2011). #4. ALEPH-2. The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds, 1, 4-5. https://archive.org/details/shulgin-index-vol-11
- (n.d.). The drug is also a weak [[monoamine oxidase inhibitor]] (MAOI), with {{Abbrlink|IC<sub>50</sub>|half-maximal inhibitory concentration}} values of 3,200{{nbsp}}nM for [[monoamine ox. https://doi.org/10.1016/s0024-3205(00)00906-11
- (2019). Amphetamine Derivatives as Monoamine Oxidase Inhibitors. Front Pharmacol, 10. https://doi.org/10.3389/fphar.2019.015901
- (n.d.). 21 U.S.C. § 813 - Treatment of controlled substance analogues. United States House of Representatives Office of the Law Revision Counsel. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section813&num=0&edition=prelim1
Further Reading
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the ALEPH-2 article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.